Methotrexate-d3 – 10 mg

Brand:
Cayman
CAS:
432545-63-6
Storage:
4
UN-No:
Non-Hazardous - /

Methotrexate-d3 is intended for use as an internal standard for the quantification of MTX (Item No. 13960) by GC- or LC-MS. MTX is similar in structure to folic acid (Item No. 20515) and aminopterin (Item No. 21802). It acts by inhibiting the metabolism of folic acid and blocking key enzymes in the synthesis of purines and pyrimidines required for cell proliferation.{21827,21826} MTX is known to induce adenosine release, which mediates many of its anti-inflammatory effects, including the reduction of proinflammatory cytokines.{21826,21828,21830} Formulations containing MTX have been used in the treatment of cancer, autoimmune diseases, ectopic pregnancy, and for the induction of medical abortions.{21829,7669} MTX formulations are considered the gold standard of disease-modifying antirheumatic drug (DMARD) therapy to treat both the immune-inflammatory and joint destructive processes of rheumatoid arthritis.{11121}  

 

Out of stock

SKU: 22378 - Category:

Description

An internal standard for the quantification of methotrexate by GC- or LC-MS


Formal name: N-[4-[[(2,4-diamino-6-pteridinyl)methyl]methyl-d3-amino]benzoyl]-L-glutamic acid

Synonyms:  Amethopterin-d3|MTX-d3

Molecular weight: 457.5

CAS: 432545-63-6

Purity: ≥99% deuterated forms (d1-d3)

Formulation: A solid


Application|Mass Spectrometry||Product Type|Biochemicals|Analytical Standards||Product Type|Biochemicals|Isotopically Labeled Standards|Deuterium||Product Type|Biochemicals|Small Molecule Inhibitors|MMPs||Product Type|Biochemicals|Small Molecule Inhibitors|Nucleic Acid Turnover/Signaling||Research Area|Cancer||Research Area|Immunology & Inflammation|Autoimmunity|Rheumatoid Arthritis